tradingview.com

Aurobindo Pharma Q1FY27 EBITDA rises as PenG ramp-up and guidance stay on track

Aurobindo Pharma logoAurobindo Pharma
Sig2.35Sen+4.15Env0.00Soc0.00Gov0.00

Prabhudas Lilladher’s research report highlights that Aurobindo Pharma’s Q1FY27 adjusted EBITDA rose to INR 19.2bn, 20% YoY, and was 4% above estimates, aided partly by currency tailwinds. The company maintained its 21% OPM guidance for FY27E. Near-term focus is ramping PenG at the Vizag plant, with growth drivers including vaccines, injectables, biosimilars and PLI; FY27E/FY28E EPS rises 4–7% factoring the Lannet acquisition.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro